

World Journal of *Gastrointestinal Surgery*

World J Gastrointest Surg 2024 October 27; 16(10): 3074-3380



EDITORIAL

- 3074 Changes over time in treatment for obstructive jaundice
Aoki H
- 3078 Single incision laparoscopic surgery for hepatocellular carcinoma
Karabicak I, Yildirim K, Gursel MF, Malazgirt Z
- 3084 Impact of liver metastasis on immunotherapy in gastric carcinoma
Chalkoo M, Bhat MY, Wani YH
- 3087 Urgent need for prognostic markers for hepatocellular carcinoma in the light of genomic instability and non-coding RNA signatures
Velikova T, Gulinac M
- 3091 Advancing perioperative optimization in Crohn's disease surgery with machine learning predictions
Nardone OM, Castiglione F, Maurea S
- 3094 Exploring the landscape of minimally invasive pancreatic surgery: Progress, challenges, and future directions
Donisi G, Zerbi A

ORIGINAL ARTICLE**Case Control Study**

- 3104 Three-dimensional printing for preoperative rehearsal and intraoperative navigation during laparoscopic rectal cancer surgery with left colic artery preservation
Zhao ZX, Hu ZJ, Yao RD, Su XY, Zhu S, Sun J, Yao Y

Retrospective Cohort Study

- 3114 Local excision of early rectal cancer: A multi-centre experience of transanal endoscopic microsurgery from the United Kingdom
Farid A, Tutton M, Thambi P, Gill T, Khan J
- 3123 Clinical significance of peri-appendiceal abscess and phlegmon in acute complicated appendicitis patients undergoing emergency appendectomy
Min LQ, Lu J, He HY
- 3133 Development of a novel difficulty scoring system for laparoscopic liver resection procedure in patients with intrahepatic duct stones
Luo B, Wu SK, Zhang K, Wang PH, Chen WW, Fu N, Yang ZM, Hao JC

Retrospective Study

- 3142** Serum nutritional predictive biomarkers and risk assessment for anastomotic leakage after laparoscopic surgery in rectal cancer patients
Shayimu P, Awula M, Wang CY, Jiapaer R, Pan YP, Wu ZM, Chen Y, Zhao ZL
- 3155** Impact of fast-track surgery on perioperative care in patients undergoing hepatobiliary surgery
Wang XH, Chen FF, Pan J, Jiang YF, Yao MY, Mao JL, Xu YF
- 3163** Follow-up strategy for early detection of delayed pseudoaneurysms in patients with blunt traumatic spleen injury: A single-center retrospective study
Cho SH, Kim GW, Hwang S, Lim KH
- 3171** Adjuvant chemotherapy for isolated resectable colorectal lung metastasis: A retrospective study using inverse probability treatment weighting propensity analysis
Gao Z, Wu SK, Zhang SJ, Wang X, Wu YC, Jin X
- 3185** Recurrence scoring system predicting early recurrence for patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy and portomesenteric vein resection
He H, Zou CF, Jiang YJ, Yang F, Di Y, Li J, Jin C, Fu DL
- 3202** Effects of postoperative treatment with chemotherapy and cellular immunotherapy on patients with colorectal cancer
Ding ZY, Piao Y, Jiang T, Chen J, Wang YN, Yu HY, Zheng ZD
- 3211** Postoperative serum tumor markers-based nomogram predicting early recurrence for patients undergoing radical resections of pancreatic ductal adenocarcinoma
He H, Zou CF, Yang F, Di Y, Jin C, Fu DL
- 3224** Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer
Wang YC, Feng L, Wang GP, Yu PJ, Guo C, Cai BJ, Song Y, Pan T, Lin BH, Li YD, Xiao JJ
- 3239** Risk factors and survival prediction model establishment for prognosis in patients with radical resection of gallbladder cancer
Li XF, Ma TT, Li T

Observational Study

- 3253** Surgical and non-surgical risk factors affecting the insufficiency of ileocolic anastomosis after first-time surgery in Crohn's disease patients
Cwaliński J, Lorek F, Mazurkiewicz Ł, Mazurkiewicz M, Lizurej W, Paszkowski J, Cholerzyńska H, Zasada W
- 3261** Relationship between intracranial pressure and neurocognitive function among older adults after radical resection of rectal cancer
Song B, Li LP, Wang XL, Guo Y, Li J

Prospective Study

- 3269** Prevention and management of postoperative deep vein thrombosis in lower extremities of patients with gastrointestinal tumor
Shu L, Xia CW, Pang YF

Randomized Controlled Trial

- 3277** Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy
Wang L, Diao YZ, Ma XF, Luo YS, Guo QJ, Chen XQ

Clinical and Translational Research

- 3288** Structured magnetic resonance imaging and endoanal ultrasound anal fistulas reporting template (SMART): An interdisciplinary Delphi consensus
Sudol-Szopińska I, Garg P, Mellgren A, Spinelli A, Breukink S, Iacobellis F, Kołodziejczak M, Ciesielski P, Jenssen C, SMART Collaborative Group, Santoro GA

CASE REPORT

- 3301** Formation and rupture of liver hematomas caused by intrahepatic gallbladder perforation: A case report and review of literature
Huang HW, Wang H, Leng C, Mei B
- 3312** Reassessment of palliative surgery in conversion therapy of previously unresectable hepatocellular carcinoma: Two case reports and review of literature
Zhu YB, Qin JY, Zhang TT, Zhang WJ, Ling Q
- 3321** Lung cancer metastasis-induced distal esophageal segmental spasm confirmed by individualized peroral endoscopic myotomy: A case report
Shi H, Chen SY, Xie ZF, Lin LL, Jiang Y
- 3328** Modified technical protocol for single-port laparoscopic appendectomy using needle-type grasping forceps for acute simple appendicitis: A case report
Chen Y, Fan ZQ, Fu XA, Zhang XX, Yuan JQ, Guo SG
- 3334** Massive simultaneous hepatic and renal perivascular epithelioid cell tumor benefitted from surgery and everolimus treatment: A case report
Yang HT, Wang FR, He N, She YH, Du YY, Shi WG, Yang J, Chen G, Zhang SZ, Cui F, Long B, Yu ZY, Zhu JM, Zhang GY
- 3343** Leukopenia—a rare complication secondary to invasive liver abscess syndrome in a patient with diabetes mellitus: A case report
Niu CY, Yao BT, Tao HY, Peng XG, Zhang QH, Chen Y, Liu L
- 3350** Acute gastric volvulus combined with pneumatosis coli rupture misdiagnosed as gastric volvulus with perforation: A case report
Zhang Q, Xu XJ, Ma J, Huang HY, Zhang YM

LETTER TO THE EDITOR

- 3358** Can serious postoperative complications in patients with Crohn's disease be predicted using machine learning?
Zbar AP
- 3363** Influencing factors and preventive measures of infectious complications after intestinal resection for Crohn's disease
Lv SR, Huang X, Zhou LY, Shi J, Gong CC, Wang MK, Yang JS
- 3371** Evaluation of preoperative blood markers for predicting intra-abdominal infection during colorectal cancer resection: A commentary on recent findings
Zhang SY, Chen J, Cai N
- 3374** Differential diagnosis of gastric submucosal masses and external pressure lesions
Na Y, Liu XD, Xu HM
- 3377** Contributing to the prediction of prognosis for treated hepatocellular carcinoma: Imaging aspects that sculpt the future
Lindner C

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Surgery*, Michele Ammendola, MD, Research Associate, Surgical Oncologist, Science of Health Department, Digestive Surgery Unit, University of "Magna Graecia" Medical School, Catanzaro 88100, Italy. michele.ammendola@unicz.it

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Surgery* (*WJGS, World J Gastrointest Surg*) is to provide scholars and readers from various fields of gastrointestinal surgery with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGS mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal surgery and covering a wide range of topics including biliary tract surgical procedures, biliopancreatic diversion, colectomy, esophagectomy, esophagostomy, pancreas transplantation, and pancreatectomy, *etc.*

INDEXING/ABSTRACTING

The *WJGS* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for *WJGS* as 1.8; JIF without journal self cites: 1.7; 5-year JIF: 1.9; JIF Rank: 123/290 in surgery; JIF Quartile: Q2; and 5-year JIF Quartile: Q3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Zi-Hang Xu, Production Department Director: Xiang Li, Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastrointestinal Surgery

ISSN

ISSN 1948-9366 (online)

LAUNCH DATE

November 30, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Peter Schemmer

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-9366/editorialboard.htm>

PUBLICATION DATE

October 27, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Impact of liver metastasis on immunotherapy in gastric carcinoma

Mushtaq Chalkoo, Mohd Yaqoob Bhat, Yaser Hussain Wani

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade C

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade B

P-Reviewer: Zhang XN

Received: March 19, 2024

Revised: May 24, 2024

Accepted: June 28, 2024

Published online: October 27, 2024

Processing time: 192 Days and 17.9 Hours



Mushtaq Chalkoo, Department of Surgery, Government Medical College, Srinagar 190014, Jammu and Kashmir, India

Mohd Yaqoob Bhat, Department of General Surgery, Government Medical College Srinagar, Srinagar 190010, Jammu and Kashmir, India

Yaser Hussain Wani, Post Graduate Department of Minimal Access and General Surgery, Government Medical College Srinagar, Srinagar 190010, Jammu and Kashmir, India

Co-first authors: Mushtaq Chalkoo and Yaser Hussain Wani.

Corresponding author: Mohd Yaqoob Bhat, MBBS, MS, FNB Minimal Access Surgery Resident, Department of General Surgery, Government Medical College Srinagar, Kaksarai Karan Nagar, Srinagar 190010, Jammu and Kashmir, India. dryaqoob92@gmail.com

Abstract

The editorial discusses the impact of liver metastasis on immunotherapy efficacy in gastric cancer (GC) patients. Liver metastasis can hinder the effectiveness of immunotherapy by altering the immune microenvironment, leading to systemic loss of T-cells and reduced treatment response. Studies suggest that liver metastases serve as a negative baseline factor for immunotherapy efficacy, resulting in poorer progression-free survival and objective response rates. Strategies such as liver-mediated radiotherapy may help improve treatment outcomes by reshaping the liver's immune microenvironment and reducing T-cell depletion. Understanding the complex interplay between liver metastasis and immunotherapy response is crucial for optimising patient care in GC.

Key Words: Immunotherapy; Liver metastasis; Immune tolerance; Gastric carcinoma; Hepatic Siphoning

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Liver metastasis affects the systemic immune response, reducing the efficacy of immunotherapy for gastric cancer patients with liver metastases. According to studies, the presence of liver metastases reduces the effectiveness of immunotherapy by lowering progression-free survival and objective response rates. Strategies such as liver-mediated radiation may aid in improving treatment outcomes. Understanding the intricate interplay between the two is crucial for offering the best possible treatment for stomach cancer with liver metastases.

Citation: Chalkoo M, Bhat MY, Wani YH. Impact of liver metastasis on immunotherapy in gastric carcinoma. *World J Gastrointest Surg* 2024; 16(10): 3084-3086

URL: <https://www.wjgnet.com/1948-9366/full/v16/i10/3084.htm>

DOI: <https://dx.doi.org/10.4240/wjgs.v16.i10.3084>

INTRODUCTION

This editorial comments on the article by Liu *et al*[1]. Gastric cancer (GC) ranks as the fifth most prevalent cancer globally and stands as the fourth principal contributor to cancer-related deaths worldwide[2]. Liver serves as the principal site for metastasis in GC[3]. In cases of GC accompanied by liver metastasis, the initial treatment typically involves a combination of fluoropyrimidines and platinum-based chemotherapy. Despite these efforts, the overall prognosis for patients in this situation continues to be unfavorable[4]. Thus, finding novel therapeutics for treating advanced GC represents an essential area of research.

DISCUSSION

Immunotherapy or immune checkpoint inhibitors, such as monoclonal antibodies against programmed cell death-1 or programmed cell death ligand-1 (PD-L1), have recently been demonstrated in numerous phase I and phase II trials to showcase a promising activity by restoring effective antitumor T-cell response within the tumor microenvironment and have improved overall survival for various cancers, including GC[5,6]. The efficacy of immunotherapy is linked to tumor-infiltrating lymphocytes and the expression of PD-L1 in tumors, with both subsequently serving as predictive factors[7]. Due to tissue-specific immunoregulation, the types of tumor-infiltrating lymphocytes differ across metastatic organ sites. Consequently, the response to immunotherapy varies at each metastatic site, influenced by the unique tumor-immune microenvironment[8].

Since the liver is an immunological organ and research has demonstrated hepatic immune tolerance, it is likely that liver metastases affect the effectiveness of immunotherapy by changing systemic anticancer activity, which includes the control of CD8+ and CD4+ T-cells[9]. Regarding the mechanism, new studies on mice have demonstrated that liver metastases cause antigen-specific T-cell death, eliminating activated CD8+ T-cells from the systemic circulation[10]. These results suggest that liver metastases may cause a depletion of T-cells throughout the body and might reduce the efficacy of immunotherapy[11]. Furthermore, inadequate activation of CD4+ T-cells, partial activation of CD8+ T-cells, and activation of regulatory T-cells are among the other pathways of liver-induced systemic immunological tolerance that have been documented[12].

CONCLUSION

According to recent studies, liver metastasis is a predictor of systemic advancement, tumor objective response rate and progression-free survival rate following immunotherapy, with those parameters being poorer in patients with GC and liver metastasis and vice versa[13]. Therefore, the existence of liver metastases may constitute a baseline risk that compromises the immunotherapy's effectiveness. Managing liver metastases by various means might improve the effectiveness of immunotherapy; in particular, hepatocellular siphoning of T-cells is decreased, and the immunological milieu of the liver is reshaped by liver-mediated radiotherapy[13].

FOOTNOTES

Author contributions: Chalkoo M, Bhat MY, and Wani YH designed the study; Bhat MY performed the research and typing; Wani YH performed the typing and editing the manuscript as well as analyzed the data; All authors have read and approved the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to

distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country of origin: India

ORCID number: Mushtaq Chalkoo 0000-0002-3783-6579; Mohd Yaqoob Bhat 0009-0004-7529-9948; Yaser Hussain Wani 0000-0001-5249-2164.

S-Editor: Li L

L-Editor: A

P-Editor: Che XX

REFERENCES

- Liu K, Wu CX, Liang H, Wang T, Zhang JY, Wang XT. Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis. *World J Gastrointest Surg* 2024; **16**: 700-709 [PMID: 38577087 DOI: 10.4240/wjgs.v16.i3.700]
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]
- Ni B, He X, Zhang Y, Wang Z, Dong Z, Xia X, Zhao G, Cao H, Zhu C, Li Q, Liu J, Chen H, Zhang Z. Tumor-associated macrophage-derived GDNF promotes gastric cancer liver metastasis via a GFRA1-modulated autophagy flux. *Cell Oncol (Dordr)* 2023; **46**: 315-330 [PMID: 36808605 DOI: 10.1007/s13402-022-00751-z]
- Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. *Ann Oncol* 2015; **26**: 141-148 [PMID: 25316259 DOI: 10.1093/annonc/mdu472]
- Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocho E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med* 2015; **372**: 320-330 [PMID: 25399552 DOI: 10.1056/NEJMoa1412082]
- Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2022; **23**: 234-247 [PMID: 35030335 DOI: 10.1016/S1470-2045(21)00692-6]
- Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Moktrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature* 2014; **515**: 563-567 [PMID: 25428504 DOI: 10.1038/nature14011]
- Pao W, Ooi CH, Birzele F, Ruefli-Brasse A, Cannarile MA, Reis B, Scharf SH, Schubert DA, Hatje K, Pelletier N, Spleiss O, Reed JC. Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer. *Cancer Discov* 2018; **8**: 395-402 [PMID: 29545369 DOI: 10.1158/2159-8290.CD-17-1320]
- Crispe IN. Hepatic T cells and liver tolerance. *Nat Rev Immunol* 2003; **3**: 51-62 [PMID: 12511875 DOI: 10.1038/nri981]
- Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, Chopra Z, El Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Achar RK, Sitto M, Rosen BS, Su F, Narayanan SP, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan MA, Schonewolf CA, Cuneo K, Kryczek I, Ma VT, Lao CD, Lawrence TS, Ramnath N, Wen F, Chinnaiyan AM, Cieslik M, Alva A, Zou W. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. *Nat Med* 2021; **27**: 152-164 [PMID: 33398162 DOI: 10.1038/s41591-020-1131-x]
- Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI. The Liver-Immunity Nexus and Cancer Immunotherapy. *Clin Cancer Res* 2022; **28**: 5-12 [PMID: 34285059 DOI: 10.1158/1078-0432.CCR-21-1193]
- Jenne CN, Kubes P. Immune surveillance by the liver. *Nat Immunol* 2013; **14**: 996-1006 [PMID: 24048121 DOI: 10.1038/ni.2691]
- Motoo I, Ando T, Hamashima T, Kajiuura S, Sakumura M, Ueda Y, Murayama A, Ogawa K, Tsukada K, Ueda A, Suzuki N, Nakada N, Nakashima K, Hosokawa A, Yasuda I. Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer. *Front Oncol* 2023; **13**: 1193533 [PMID: 37790758 DOI: 10.3389/fonc.2023.1193533]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

